Online at: https://researchtrendsjournal.com
Indexed Journal
ISSN No: 2584-282X
Peer Reviewed Journal

INTERNATIONAL JOURNAL OF TRENDS IN EMERGING RESEARCH AND DEVELOPMENT

Volume 4; Issue 3; 2026; Page No. 150-155

Received: 22-03-2026
Accepted: 29-04-2026
Published: 20-05-2026

In-Vivo Evaluation of a Microbiome-and Reactive Oxygen Species-Responsive Nanocarrier for Targeted Therapy of Inflammatory Bowel Disease: Therapeutic Efficacy, Microbiome Modulation and Safety Assessment

[1]Deokar Shivprasad Sanjay and [2]Dr. Umesh Kumar

[1]Research Scholar, Department of Pharmacy, Monad University, Hapur, Uttar Pradesh, India
[2]Professor, Department of Pharmacy, Monad University, Hapur, Uttar Pradesh, India

DOI: https://doi.org/10.5281/zenodo.21908927

Corresponding Author: Deokar Shivprasad Sanjay

Abstract

Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gastrointestinal tract characterized by disruption of intestinal homeostasis, epithelial barrier dysfunction, immune dysregulation, oxidative stress, and alterations in the gut microbiome. Although currently available therapies can effectively control disease activity in many patients, limitations associated with systemic exposure, incomplete response, adverse effects, and inadequate localization of therapeutic agents continue to motivate the development of targeted drug-delivery systems. The present study investigated the therapeutic potential of an optimized microbiome- and reactive oxygen species (ROS)-responsive nanocarrier developed for targeted delivery of a selected therapeutic drug in experimental IBD. Following characterization of the optimized formulation, its therapeutic performance was evaluated using an appropriate experimental model of intestinal inflammation. Animals were allocated into appropriate treatment and control groups, and disease activity was assessed using relevant clinical and physiological parameters. Histopathological examination was performed to determine structural changes in intestinal tissues. Oxidative stress and antioxidant defence were evaluated using appropriate biochemical biomarkers, while inflammatory responses were assessed through relevant cytokine measurements. Gut microbiome profiling was performed to investigate treatment-associated changes in microbial composition and/or function. Biodistribution and pharmacokinetic studies were undertaken to evaluate tissue targeting and drug exposure, while safety and toxicological parameters were assessed to determine tolerability. The overall research framework was designed to examine the interconnected relationship among nanocarrier-mediated drug delivery, microbiome modulation, oxidative stress reduction, inflammatory control, and improvement in intestinal pathology. The study provides a preclinical framework for evaluating dual-responsive nanomedicine as a potential targeted therapeutic strategy for IBD.

Keywords: Inflammatory bowel disease, nanomedicine, microbiome, reactive oxygen species, targeted drug delivery, oxidative stress, cytokines, pharmacokinetics, biodistribution, intestinal inflammation

1. Introduction

Inflammatory bowel disease represents a group of chronic gastrointestinal inflammatory disorders, principally Crohn's disease and ulcerative colitis. The clinical course of IBD is characterized by periods of active inflammation and remission, with disease manifestations ranging from intestinal discomfort and altered bowel habits to more severe tissue injury and systemic complications.

The pathogenesis of IBD is multifactorial. Abnormal interactions between the intestinal immune system and luminal microorganisms occur in the context of impaired epithelial barrier function and environmental and genetic influences. The gut microbiome is particularly important because intestinal microorganisms contribute to epithelial homeostasis, immune regulation, nutrient metabolism, and production of biologically active metabolites.

Microbial dysbiosis can disturb this equilibrium and may contribute to inflammatory signalling. At the same time,

inflammatory immune responses can modify the intestinal environment and subsequently influence microbial communities. Therefore, the relationship between microbiome alterations and IBD is dynamic and bidirectional.

Oxidative stress represents another important component of intestinal inflammation. Reactive oxygen species are generated by immune and epithelial cells and participate in antimicrobial defence and intracellular signalling. Excessive ROS production, however, can damage lipids, proteins, nucleic acids, and cellular membranes when antioxidant capacity is insufficient.

1.1 Limitations of Conventional Therapeutic Approaches

Conventional IBD treatment aims to suppress inflammation, induce remission, and maintain disease control. Depending on disease characteristics, treatment may involve anti-inflammatory agents, corticosteroids, immunomodulators, biologics, or other targeted therapies.

Despite therapeutic advances, several challenges remain. Drug response may vary among individuals, some patients develop inadequate response or loss of response, and systemic exposure may contribute to unwanted effects. Furthermore, achieving an appropriate concentration of drug at the site of intestinal inflammation remains an important drug-delivery challenge.

1.2 Nanocarriers as Targeted Delivery Platforms

Nanocarriers can encapsulate therapeutic molecules and modify their distribution, stability, and release behaviour. Their surfaces can also be engineered to influence interactions with mucus, epithelial cells, and biological molecules. The therapeutic value of nanocarriers cannot be established solely from physicochemical characterization. *In-vivo* investigation is required to determine whether the formulation produces meaningful improvement in disease activity, intestinal pathology, oxidative stress, inflammation, and overall safety.

1.3 Rationale for Microbiome- and ROS-Responsive Delivery

The dual-responsive nanocarrier investigated in the present study is based on the concept that pathological intestinal conditions can serve as endogenous signals.



1.4 Aim

The aim of this study was to evaluate the *in-vivo* therapeutic efficacy, microbiome-related effects, oxidative-stress modulation, inflammatory response, biodistribution, pharmacokinetics, and safety of an optimized microbiome- and ROS-responsive nanocarrier for targeted treatment of experimental IBD.

1.5 Objectives

- To establish an appropriate experimental model of IBD.
- To evaluate the therapeutic effect of the optimized nanocarrier on disease activity.
- To assess changes in body weight, disease activity, stool characteristics, and other relevant physiological parameters.
- To examine intestinal histopathological changes following treatment.
- To determine the effect of treatment on oxidative stress and ROS-associated biomarkers.
- To evaluate antioxidant defence mechanisms.
- To determine changes in inflammatory cytokines.
- To investigate treatment-associated alterations in the gut microbiome.
- To evaluate biodistribution and intestinal targeting.
- To compare pharmacokinetic behaviour of the nanocarrier formulation with the free drug or appropriate conventional formulation.
- To assess the safety and toxicological profile of the optimized formulation.
- To establish relationships among microbiome restoration, ROS reduction, inflammatory control, and disease improvement.

2. Materials and Methods

2.1 Experimental Animals

Appropriate laboratory animals should be selected according to the approved experimental protocol. Animals should be maintained under standardized environmental conditions with appropriate access to food and water.

All procedures involving animals must be conducted in accordance with applicable institutional and national ethical requirements.

2.2 Experimental IBD Model

An experimentally validated model of intestinal inflammation should be employed according to the approved study protocol. The selected model should reproduce relevant features of intestinal inflammation, including epithelial injury, inflammatory infiltration, oxidative stress, and measurable changes in disease activity.

The final manuscript should specify the exact model, induction method, dose, duration, and ethical approval information based exclusively on the actual experimental protocol.

2.3 Experimental Groups

Table 1: A suitable experimental design may include

Group	Experimental condition
Group I	Healthy control
Group II	IBD/disease control
Group III	Free drug treatment
Group IV	Conventional/non-responsive formulation
Group V	Optimized responsive nanocarrier
Additional group	Vehicle/sham control where required

The precise number of animals and group allocation should correspond to the approved experimental design.

Randomization and blinding should be used where feasible to minimize experimental bias.

2.4 Treatment Protocol

Following establishment of experimental disease, animals were treated according to the predetermined treatment schedule.

The treatment protocol should document

- dose;
- route of administration;
- frequency;
- treatment duration;
- formulation concentration; and
- timing relative to disease induction.

Actual experimental values must be inserted from the laboratory protocol.

2.5 Disease Activity Assessment

Disease activity should be evaluated using predetermined clinical parameters.

Potential measures include

- body-weight change;
- stool consistency;
- visible blood;
- disease activity index;
- food and water intake where relevant;
- intestinal length at termination; and
- gross pathological changes.

A composite disease activity score may be used when appropriately validated for the selected experimental model.

2.6 Histopathological Evaluation

Following termination of the experiment, intestinal tissue should be collected, processed, sectioned, stained, and examined using an appropriate histopathological procedure.

The evaluation should consider parameters such as

- epithelial integrity;
- mucosal architecture;
- inflammatory-cell infiltration;
- crypt architecture;
- ulceration;
- edema;
- tissue damage; and
- regeneration.

A predefined histological scoring system should be applied to reduce subjective interpretation.

2.7 Oxidative Stress Analysis

Intestinal tissues or other relevant biological samples should be analyzed for oxidative-stress biomarkers.

Potential parameters include markers of lipid peroxidation and oxidative damage, together with measures of antioxidant defence.

The exact biomarkers should correspond to the validated experimental methodology used in the study.

2.8 Antioxidant Defence

The antioxidant system can be evaluated by measuring relevant enzymatic and non-enzymatic components.

Possible parameters include

- superoxide dismutase;
- catalase;
- glutathione-related measures;
- glutathione peroxidase; and
- other validated antioxidant indicators.

Interpretation should consider multiple biomarkers rather than relying on a single indicator of antioxidant status.

2.9 Inflammatory Cytokine Analysis

Inflammatory cytokines should be measured using an appropriately validated analytical method.

Depending on the experimental model and objectives, relevant inflammatory mediators may include cytokines associated with innate and adaptive inflammatory pathways.

2.10 Gut Microbiome Profiling

Fecal or intestinal samples should be collected using standardized procedures for microbiome analysis.

Microbiome profiling may involve sequencing-based characterization followed by appropriate bioinformatic analysis.

The analysis can include

- microbial diversity;
- community composition;
- relative abundance;
- treatment-associated changes;
- potentially relevant microbial functions; and
- relationships between microbial changes and disease parameters.

An important principle is that changes in relative abundance should not automatically be interpreted as proof of improved intestinal health. Functional and clinical correlations provide stronger evidence.

2.11 Biodistribution and Targeting Evaluation

The biodistribution of the therapeutic drug or appropriately labeled nanocarrier should be investigated following administration.

Relevant tissues may include

- intestinal segments;
- colon;
- liver;
- spleen;
- kidney; and
- other tissues required by the study design.

2.12 Pharmacokinetic Evaluation

Pharmacokinetic parameters should be determined using an appropriate analytical method.

Depending on the sampling design, parameters may include

- maximum concentration;
- time to maximum concentration;
- area under the concentration-time curve;
- elimination characteristics; and
- apparent residence time.

2.13 Safety and Toxicological Evaluation

Safety should be evaluated using clinical observations, body-weight monitoring, organ assessment, biochemical parameters, and histological examination where appropriate.

The safety assessment should determine whether the optimized nanocarrier produces evidence of toxicity beyond the therapeutic effect.

For microbiome-responsive systems, microbiome-related safety should also be considered because unintended long-term disruption of microbial ecology could represent an important concern.

2.14 Statistical Analysis

Data should be analyzed using statistical methods appropriate to the experimental design.

Continuous variables should be assessed for distributional assumptions before selecting parametric or non-parametric tests. Multiple-group comparisons should account for multiple testing where appropriate.

Correlations can be used to explore relationships between

Microbiome → ROS → Cytokines → Histopathology → Disease activity

3. Results and Discussion

3.1 Establishment of Experimental IBD

Successful establishment of experimental IBD should be demonstrated through disease-associated clinical, physiological, biochemical, and/or histological changes compared with healthy controls.

3.2 Effect on Disease Activity

The optimized nanocarrier should be evaluated against the disease control and appropriate comparator groups.

Improvement in disease activity may be reflected by restoration of body weight, improvement in stool characteristics, reduction in visible bleeding, improvement in disease activity scores, and reduction in gross intestinal abnormalities.

Importantly, therapeutic efficacy should be evaluated using multiple independent parameters rather than a single clinical measurement.

3.3 Histopathological Improvement

Histopathology provides direct information regarding tissue-level consequences of treatment.

An effective treatment would be expected to reduce inflammatory-cell infiltration, epithelial disruption, mucosal injury, ulceration, and crypt abnormalities relative to the disease-control group.

3.4 Reduction of Oxidative Stress

A major mechanistic endpoint of the present research is the ability of the responsive nanocarrier to reduce oxidative stress.

If treatment produces a statistically significant reduction in oxidative-damage markers compared with the disease control, this may support an antioxidant effect.

Greater improvement with the nanocarrier compared with the free drug would provide additional evidence that the delivery system contributes to therapeutic performance.

3.5 Restoration of Antioxidant Defence

Inflammatory oxidative stress can be accompanied by impairment of endogenous antioxidant defence.

Treatment-associated normalization of antioxidant enzymes or glutathione-related parameters could indicate restoration of redox balance.

The strongest interpretation would arise when oxidative-damage markers and antioxidant-defence parameters change in complementary directions.

3.6 Modulation of Inflammatory Cytokines

Inflammatory cytokine analysis provides molecular evidence supporting the observed clinical and histological effects.

A reduction in relevant inflammatory cytokines following nanocarrier treatment would support suppression of inflammatory activity.

3.7 Gut Microbiome Modulation

Microbiome analysis represents a distinguishing component of Paper 2.

Treatment-associated changes in microbial diversity or community structure can be compared between healthy controls, disease controls, free-drug treatment, conventional formulation, and responsive nanocarrier groups.

The key objective is not simply to demonstrate that microbial composition changed, but to determine whether microbiome alterations are associated with restoration of intestinal homeostasis.

Potential analytical relationships include



Any particular bacterial taxa or functional pathways should only be discussed if they are actually identified in the experimental data.

3.8 Biodistribution and Intestinal Targeting

Biodistribution data can establish whether nanocarrier administration modifies the distribution of the therapeutic drug.

Enhanced drug accumulation in relevant intestinal tissues, if demonstrated experimentally, would support the targeting hypothesis.

However, increased intestinal concentration alone does not prove disease-specific targeting. Stronger evidence would require comparison between inflamed and non-inflamed intestinal tissues and appropriate systemic organs.

3.9 Pharmacokinetic Advantages

Comparison of the nanocarrier and free-drug profiles can reveal whether encapsulation changes systemic exposure and drug residence.

A potentially favourable formulation would combine

adequate intestinal drug availability with controlled systemic exposure.
The interpretation should be based on experimentally determined pharmacokinetic parameters rather than assumed advantages of nanoparticle delivery.

3.10 Safety Evaluation

The therapeutic advantage of a nanocarrier must be considered alongside safety.
If the optimized formulation produces no meaningful adverse clinical, biochemical, organ-level, or histological effects under the experimental conditions, this would support its preclinical tolerability.
Nevertheless, absence of toxicity in a short-term animal experiment does not establish long-term human safety. Repeated-dose and extended-duration studies would remain necessary.

3.11 Integrated Microbiome–ROS–Inflammation Mechanism

The major scientific contribution of Paper 2 should be the integration of multiple biological outcomes.

The proposed mechanism can be represented as



This integrated model provides a mechanistic framework connecting the nanocarrier's design characteristics with its biological effects.

3.12 Correlation Analysis

Table 2: An important additional analysis would be to investigate correlations between biological endpoints.

Variable	Potentially correlated outcome
Microbial diversity	Disease activity
Microbial abundance	Cytokine level
ROS marker	Histological score
Antioxidant activity	Disease severity
Cytokines	Tissue injury
Intestinal drug concentration	Therapeutic response

Such analyses can help identify biological relationships, although they should be presented as associations unless supported by appropriate mechanistic experimentation.

4. Overall Discussion

The principal objective of this investigation is to determine whether the dual-responsive nanocarrier provides a therapeutic advantage beyond that achieved with the free drug.

The most informative comparison is therefore
Free drug vs conventional formulation vs dual-responsive nanocarrier

A superior formulation would ideally demonstrate several characteristics simultaneously

1. improved intestinal drug exposure;
2. controlled drug distribution;
3. reduced disease activity;
4. improved intestinal histology;
5. reduced oxidative stress;
6. improved antioxidant defence;
7. reduced inflammatory cytokines;
8. beneficial microbiome-associated changes; and
9. acceptable safety.

A formulation demonstrating improvement across these interconnected endpoints would provide stronger evidence than one producing improvement in only a single outcome.

5. Conclusion

The present research paper evaluates the *in-vivo* therapeutic potential of a microbiome- and ROS-responsive nanocarrier developed for targeted drug delivery in IBD. Unlike formulation-focused investigations, this study emphasizes the biological and therapeutic consequences of nanocarrier administration.
The research framework integrates clinical disease activity, intestinal histopathology, oxidative stress, antioxidant defence, inflammatory cytokines, gut microbiome profiling, biodistribution, pharmacokinetics, and safety.
The central hypothesis is that a nanocarrier capable of responding to disease-associated microbial and oxidative conditions may provide more localized and controlled drug delivery than the free therapeutic agent. If supported by the experimental results, coordinated improvement in disease activity, tissue pathology, oxidative balance, inflammatory biomarkers, and microbiome-associated parameters would provide evidence for an integrated therapeutic mechanism.

6. References

1. Colon-targeted oral nanoparticles based on ROS-scavenging hydroxyethyl starch-curcumin conjugates for efficient inflammatory bowel disease therapy. Int J Pharm. 2022. doi:10.1016/j.ijpharm.2022.121884.
2. Inflammation-specific targeted carriers for local drug delivery to inflammatory bowel disease. J Control Release. 2022.
3. Reactive oxygen species responsive nanoplatforms as smart drug delivery systems for gastrointestinal tract targeting. Biopolymers. 2020. doi:10.1002/bip.23336.
4. Stimulus-responsive drug delivery nanoplatforms for inflammatory bowel disease therapy. Acta Biomater. 2024;188:27-47. doi:10.1016/j.actbio.2024.09.007.
5. Beloqui A, Coco R, Memvanga PB, *et al*. Targeting inflammatory bowel diseases by nanocarriers loaded with small and biopharmaceutical anti-inflammatory drugs. Curr Pharm Des. 2016;22(40):6192-6206. doi:10.2174/1381612822666160211141813.
6. Beloqui A, Coco R, Memvanga PB, Ucakar B, des Rieux A, Préat V. pH-sensitive nanoparticles for colonic delivery of curcumin in inflammatory bowel disease. Int J Pharm. 2014.
7. Fakhoury M, Negrulj R, Mooranian A, Al-Salami H. Nanocarriers for the treatment of inflammatory bowel disease. J Control Release. 2014;189:1-11.

8. Gevers D, Kugathasan S, Denson LA, *et al*. The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe. 2014;15(3):382-392. doi:10.1016/j.chom.2014.02.005.
9. Halfvarson J, Brislawn CJ, Lamendella R, *et al*. Dynamics of the human gut microbiome in inflammatory bowel disease. Nat Microbiol. 2017;2:17004. doi:10.1038/nmicrobiol.2017.4.
10. Hu S, Zhao R, Xu Y, Gu Z, Zhu B, Hu J. Orally-administered nanomedicine systems targeting colon inflammation for the treatment of inflammatory bowel disease: latest advances. J Mater Chem B. 2024;12:13-38. doi:10.1039/D3TB02302H.
11. Lamprecht A. Nanoparticles and microparticles for drug targeting to the inflamed intestinal mucosa. J Pharm Pharmacol. 2010;62(11):1385-1397.
12. Lavelle A, Sokol H. Gut microbiota-derived metabolites as key actors in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2020;17:223-237. doi:10.1038/s41575-019-0258-z.
13. Li H, Pan M, Li Y, *et al*. Nanomedicine: the new trend and future of precision medicine for inflammatory bowel disease. Chin Med J. 2024;137(24):3073-3082. doi:10.1097/CM9.0000000000003413.
14. Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014;14:329-342. doi:10.1038/nri3661.
15. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347(6):417-429. doi:10.1056/NEJMra020831.
16. Rezaie A, Parker RD, Abdollahi M. Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause? Dig Dis Sci. 2007;52:2015-2021.
17. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol. 2009;9:313-323. doi:10.1038/nri2515.
18. Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology. 2008;134(2):577-594. doi:10.1053/j.gastro.2007.11.059.
19. Schirmer M, Denson L, Vlamakis H, *et al*. Microbial genes and pathways in inflammatory bowel disease. Nat Rev Microbiol. 2018;17:497-511.
20. Shi C, Li Y, Zhang X, *et al*. A nanoparticulate dual scavenger for targeted therapy of inflammatory bowel disease. Sci Adv. 2022;8(4):eabj2372. doi:10.1126/sciadv.abj2372.
21. Shi Y, *et al*. Engineered biomimetic nanoparticles with targeted delivery of chlorothiazide for the treatment of inflammatory bowel disease. Angew Chem Int Ed. 2026;65(16):e25914. doi:10.1002/anie.202525914.
22. Taghipour YD, Bahramsoltani R, Marques AM, *et al*. A systematic review of nano formulation of natural products for the treatment of inflammatory bowel disease: drug delivery and pharmacological targets. DARU J Pharm Sci. 2018;26:229-239. doi:10.1007/s40199-018-0222-4.
23. Turner JR. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol. 2009;9:799-809. doi:10.1038/nri2653.
24. Wan X, Zhang C, Lei P, *et al*. Precision therapeutics for inflammatory bowel disease: advancing ROS-responsive nanoparticles for targeted and multifunctional drug delivery. J Mater Chem B. 2025;13(10):3245-3269. doi:10.1039/D4TB02868F.